Rubexet 10mg / 5ml. 50mg / 25ml. 200mg / 100ml Infusion
PDF Leaflet Revision Date: 2 October 2014
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including acute leukaemias and solid tumours.
Dosage (summary)
60-90 mg/mu00b2 every 3-4 weeks; adjust for hepatic impairment.
Special Populations
- Elderly
- Hepatic impairment
- Obese patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; crosses placenta and enters breast milk.
Key Drug Interactions
- Additive toxicity with other cytotoxic agents
- Cardiotoxic drugs
Contraindications
- Hypersensitivity to doxorubicin
- Persistent myelosuppression
- Hepatic impairment
- Myocardial insufficiency
Common side effects
- Nausea
- Vomiting
- Bone marrow depression
- Alopecia
Counselling Points
- Avoid pregnancy during treatment
- Use effective contraception
- Report signs of extravasation immediately
Serious warnings
- Severe cardiotoxicity risk
- Monitor cardiac function
- Risk of secondary leukaemia
Important Disclaimer
The Rubexet 10mg / 5ml. 50mg / 25ml. 200mg / 100ml Infusion professional information leaflet below is the property of Accord Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
